Skip to content

Study · Animal study (in vivo) · rat · 2023

8 results

Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats.

Tepes M, Krezic I, Vranes H, Smoday IM, Kalogjera L, Zizek H, Vukovic V, Oroz K, Kovac KK, Madzar Z, Rakic M, Miskic B and 13 more

Show all authors

Sikiric S, Barisic I, Strbe S, Antunovic M, Novosel L, Kavelj I, Vlainic J, Dobric I, Staresinic M, Skrtic A, Seiwerth S, Blagaic AB, Sikiric P

Pharmaceuticals (Basel, Switzerland)2 Nov 2023Cited by 11 (Europe PMC)

PMID38004420 (opens in a new tab)PMCIDPMC10675657 (opens in a new tab)DOI10.3390/ph16111554 (opens in a new tab)PepBankPUB-38004420
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Given in reperfusion, the use of stable gastric pentadecapeptide BPC 157 is an effective therapy in rats. It strongly counteracted, as a whole, decompression/reperfusion-induced occlusion/occlusion-like syndrome following the worst circumstances of acute abdominal compartment and intra-abdominal hypertension, grade III and grade IV, as well as compression/ischemia-occlusion/occlusion-like syndrome. Before decompression (calvariectomy, laparotomy), rats had long-lasting severe intra-abdominal hypertension, grade III (25 mmHg/60 min) (i) and grade IV (30 mmHg/30 min; 40 mmHg/30 min) (ii/iii), and severe occlusion/occlusion-like syndrome. Further worsening was caused by reperfusion for 60 min (i) or 30 min (ii/iii). Severe vascular and multiorgan failure (brain, heart, liver, kidney, and gastrointestinal lesions), widespread thrombosis (peripherally and centrally) severe arrhythmias, intracranial (superior sagittal sinus) hypertension, portal and caval hypertension, and aortal hypotension were aggravated. Contrarily, BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times eliminated/attenuated venous hypertension (intracranial (superior sagittal sinus), portal, and caval) and aortal hypotension and counteracted the increases in organ lesions and malondialdehyde values (blood ˃ heart, lungs, liver, kidney ˃ brain, gastrointestinal tract). Vascular recovery promptly occurred (i.e., congested inferior caval and superior mesenteric veins reversed to the normal vessel presentation, the collapsed azygos vein reversed to a fully functioning state, the inferior caval vein-superior caval vein shunt was recovered, and direct blood delivery returned). BPC 157 therapy almost annihilated thrombosis and hemorrhage (i.e., intracerebral hemorrhage) as proof of the counteracted general stasis and Virchow triad circumstances and reorganized blood flow. In conclusion, decompression/reperfusion-induced occlusion/occlusion-like syndrome counteracted by BPC 157 therapy in rats is likely for translation in patients. It is noteworthy that by rapidly counteracting the reperfusion course, it also reverses previous ischemia-course lesions, thus inducing complete recovery.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with intra-abdominal hypertension, BPC‑157 given in reperfusion strongly counteracted the decompression/reperfusion-induced occlusion-like syndrome as a whole.

    In plain wordsIn rats with high belly pressure, BPC‑157 given at reperfusion strongly counteracted the blood vessel and organ damage that followed.

    Peptide
    BPC-157
    Outcome
    DecreaseDecompression/reperfusion-induced occlusion-like syndrome
    Study

    ratn: not reported in source

    Reperfusion after intra-abdominal hypertension (grade III and IV)
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    It strongly counteracted, as a whole, decompression/reperfusion-induced occlusion/occlusion-like syndrome following the worst circumstances of acute abdominal compartment and intra-abdominal hypertension, grade III and grade IV, as well as compression/ischemia-occlusion/occlusion-like syndrome.
    2 context sentences
    Summary · context
    rats had long-lasting severe intra-abdominal hypertension, grade III (25 mmHg/60 min) (i) and grade IV (30 mmHg/30 min; 40 mmHg/30 min) (ii/iii)
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with intra-abdominal hypertension, BPC‑157 therapy eliminated or attenuated intracranial, portal and caval venous hypertension after reperfusion.

    In plain wordsIn rats with high belly pressure, BPC‑157 removed or lessened high pressure in veins after reperfusion.

    Peptide
    BPC-157
    Outcome
    DecreaseVenous hypertension (intracranial, portal, caval)
    Study

    ratn: not reported in source

    Reperfusion after intra-abdominal hypertension (grade III and IV)
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    eliminated/attenuated venous hypertension (intracranial (superior sagittal sinus), portal, and caval) and aortal hypotension
    2 context sentences
    Summary · context
    rats had long-lasting severe intra-abdominal hypertension, grade III (25 mmHg/60 min) (i) and grade IV (30 mmHg/30 min; 40 mmHg/30 min) (ii/iii)
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with intra-abdominal hypertension, BPC‑157 therapy eliminated or attenuated aortal hypotension after reperfusion.

    In plain wordsIn rats with high belly pressure, BPC‑157 removed or lessened low aortic pressure after reperfusion.

    Peptide
    BPC-157
    Outcome
    IncreaseAortal hypotension
    Study

    ratn: not reported in source

    Reperfusion after intra-abdominal hypertension (grade III and IV)
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    eliminated/attenuated venous hypertension (intracranial (superior sagittal sinus), portal, and caval) and aortal hypotension
    2 context sentences
    Summary · context
    rats had long-lasting severe intra-abdominal hypertension, grade III (25 mmHg/60 min) (i) and grade IV (30 mmHg/30 min; 40 mmHg/30 min) (ii/iii)
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with intra-abdominal hypertension, BPC‑157 therapy counteracted the reperfusion-induced increases in organ lesions.

    In plain wordsIn rats with high belly pressure, BPC‑157 counteracted the rise in organ damage after reperfusion.

    Peptide
    BPC-157
    Outcome
    DecreaseOrgan lesions
    Study

    ratn: not reported in source

    Reperfusion after intra-abdominal hypertension (grade III and IV)
    Outcome group
    Cardiovascular events · Whole body
    Studied dose
    10 µg/kg and 10 ng/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    counteracted the increases in organ lesions and malondialdehyde values (blood ˃ heart, lungs, liver, kidney ˃ brain, gastrointestinal tract).
    2 context sentences
    Summary · context
    rats had long-lasting severe intra-abdominal hypertension, grade III (25 mmHg/60 min) (i) and grade IV (30 mmHg/30 min; 40 mmHg/30 min) (ii/iii)
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats with intra-abdominal hypertension, BPC‑157 therapy counteracted the reperfusion-induced increases in malondialdehyde values in blood and organs.

    In plain wordsIn rats with high belly pressure, BPC‑157 counteracted the rise of a tissue-damage marker after reperfusion.

    Peptide
    BPC-157
    Outcome
    DecreaseMalondialdehyde values
    Study

    ratn: not reported in source

    Reperfusion after intra-abdominal hypertension (grade III and IV)
    Outcome group
    Inflammation markers · Whole body
    Studied dose
    10 µg/kg and 10 ng/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    counteracted the increases in organ lesions and malondialdehyde values (blood ˃ heart, lungs, liver, kidney ˃ brain, gastrointestinal tract).
    2 context sentences
    Summary · context
    rats had long-lasting severe intra-abdominal hypertension, grade III (25 mmHg/60 min) (i) and grade IV (30 mmHg/30 min; 40 mmHg/30 min) (ii/iii)
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with intra-abdominal hypertension, BPC‑157 therapy restored congested veins to normal presentation, restored azygos vein function and the inferior-superior caval vein shunt, and returned direct blood delivery.

    In plain wordsIn rats with high belly pressure, BPC‑157 helped blocked veins return to normal and restored blood flow routes.

    Peptide
    BPC-157
    Outcome
    IncreaseVascular recovery
    Study

    ratn: not reported in source

    Reperfusion after intra-abdominal hypertension (grade III and IV)
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Vascular recovery promptly occurred (i.e., congested inferior caval and superior mesenteric veins reversed to the normal vessel presentation, the collapsed azygos vein reversed to a fully functioning state, the inferior caval vein-superior caval vein shunt was recovered, and direct blood delivery returned).
    2 context sentences
    Summary · context
    rats had long-lasting severe intra-abdominal hypertension, grade III (25 mmHg/60 min) (i) and grade IV (30 mmHg/30 min; 40 mmHg/30 min) (ii/iii)
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with intra-abdominal hypertension, BPC‑157 therapy almost eliminated thrombosis.

    In plain wordsIn rats with high belly pressure, BPC‑157 almost removed blood clots.

    Peptide
    BPC-157
    Outcome
    DecreaseThrombosis
    Study

    ratn: not reported in source

    Reperfusion after intra-abdominal hypertension (grade III and IV)
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 therapy almost annihilated thrombosis and hemorrhage (i.e., intracerebral hemorrhage) as proof of the counteracted general stasis and Virchow triad circumstances and reorganized blood flow.
    2 context sentences
    Summary · context
    rats had long-lasting severe intra-abdominal hypertension, grade III (25 mmHg/60 min) (i) and grade IV (30 mmHg/30 min; 40 mmHg/30 min) (ii/iii)
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with intra-abdominal hypertension, BPC‑157 therapy almost eliminated hemorrhage, including intracerebral hemorrhage.

    In plain wordsIn rats with high belly pressure, BPC‑157 almost removed bleeding, including bleeding in the brain.

    Peptide
    BPC-157
    Outcome
    DecreaseHemorrhage (intracerebral)
    Study

    ratn: not reported in source

    Reperfusion after intra-abdominal hypertension (grade III and IV)
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 µg/kg and 10 ng/kg · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 therapy almost annihilated thrombosis and hemorrhage (i.e., intracerebral hemorrhage) as proof of the counteracted general stasis and Virchow triad circumstances and reorganized blood flow.
    2 context sentences
    Summary · context
    rats had long-lasting severe intra-abdominal hypertension, grade III (25 mmHg/60 min) (i) and grade IV (30 mmHg/30 min; 40 mmHg/30 min) (ii/iii)
    Summary · context
    BPC 157 therapy (10 µg/kg, 10 ng/kg sc) given at 3 min reperfusion times

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.